Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PLX-R18 for HS-ARS
NCT03797040Phase 1Unknown
- Sponsor
- Pluri Inc.
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of avoplacel in Acute Radiation Syndrome (ARS), sponsored by Pluri Inc. Primary endpoint: Any Adverse Reaction at Week 260. Status: unknown.
02
Drugs
avoplacel
03
Conditions
Acute Radiation Syndrome (ARS)
Beyond the preview
Go deeper on NCT03797040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797040.